Webinar Video | Life Sciences Session #1: What’s new in the parallel world of parallel trade?
In our first Life Sciences Session, our experts Philippe de Jong and Kirian Claeyé talk you through a number of recent decisions and developments in the field of parallel trade of pharmaceuticals, medical devices and plant protection products, including:
- The rebranding of generics to original brand reference products
- The impact of the falsified medicines framework on parallel trade
- Further points of attention when verifying in light of the BMS conditions
Recommended articles
Belgian Constitutional Court strikes down pharma industry ‘unavailability contribution’
The Belgian Constitutional Court (“CC”), on 6 November 2025, annulled some provisions of the Law of 18 May 2024 containing various provisions on health and finance, striking down the pharma industry ‘unavailability contribution’. Background Parts of the above Law sought to protect patients from bearing additional costs when reimbursable medicines become unavailable and must be […]
Read on
Food Hygiene for Fish: EU General Court Requires Scientific Basis to “Clarify” the Law
Food company Mowi Poland successfully challenged the European Commission’s new hygiene rules governing ‘stiffening’—a specialised fish processing technique—on the grounds that the Commission failed to obtain mandatory scientific consultation. While the Commission defended its approach by characterising the measures as mere “clarification” of existing law and citing industry guidelines as support, the EU General Court […]
Read on
Combination therapies in Belgium: how to collaborate without breaching competition law
As the landscape of modern medicine evolves, combination therapies—those that use two or more distinct medicines, often from different companies—are becoming increasingly vital, especially in treating complex diseases like cancer. These therapies promise improved clinical outcomes through synergistic mechanisms of action. However, the reimbursement process for such therapies presents significant regulatory and legal challenges, particularly […]
Read on